The new blood test will help physicians prevent major cardiovascular events in women with lupus. Credit: Ahmad Ardity / Pixabay.

AMPEL BioSolutions has unveiled a new genetic precision medicine test that can predict heart disease at an early stage in women with lupus.

The new CardioGENE lab test also provides decision support for prophylactic therapies. 

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It uses blood samples to identify inherited genetic markers that drive pathways with the capacity to be targeted by drugs that can prevent cardiovascular issues.

The company stated that for the last few years, the new blood test was only a concept but now it will be able to serve as a decision-support biomarker test.

According to AMPEL BioSolutions, the new technique of connecting genetic predisposition to molecular pathways that are targeted by drugs could help healthcare providers identify the cardiovascular disease risk in individuals diagnosed with lupus and then choose suitable preventative therapies.

AMPEL BioSolutions co-founder, president and chief scientific officer Amrie Grammer said: “CardioGENE marks a diversification of AMPEL’s portfolio into genetic testing, and we are extremely excited to share our results.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We are confident that CardioGENE will make a difference in the lives of lupus patients, especially young women, who disproportionately suffer from the disease’s cardiovascular impacts.”

The company stated that the new CardioGENE lab test marks its expansion into genetic testing as a second platform technology along with its existing work in RNA analytics and machine learning.

Funded by a US Department of Defense (DoD) Impact Award, the test emerged from AMPEL BioSolutions’ partnership with Wake Forest.

AMPEL BioSolutions co-founder, CEO and chief medical officer Peter Lipsky said: “This research not only contributes to our understanding of the genetic basis of the increased frequency of cardiovascular events in patients living with lupus, but also provides practical information on new molecular pathways contributing to atherosclerotic cardiovascular disease.

“We believe this work will usher in new approaches to ameliorate one of the leading causes of death in lupus patients.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact